The EuroNet paediatric hodgkin network - Modern imaging data management for real time central review in multicentre trials

Klinische Padiatrie

Volumn 225, Issue 6, 2013, Pages 357-361

  Kurch, Lars ^a   Mauz Korholz C ^b   Bertling, S ^c   Wallinder, M ^c   Kaminska, M ^a   Marwede, D ^a   Tchavdarova, L ^a   Georgi, T W ^a   Elsner, A ^c   Barthel, A ^a   Stoevesandt, D ^b   Hasenclever, D ^d   Sattler, B ^a   Sabri, O ^a   Korholz D ^b   Kluge, R ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c HERMES MEDICAL SOLUTIONS   (Sweden)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

cross sectional imaging; data management; data network; data safety; euronet PHL trials; paediatric hodgkin lymphoma

Indexed keywords

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER NETWORK; COMPUTER SECURITY; DIAGNOSTIC IMAGING; DIGITAL IMAGING AND COMMUNICATIONS IN MEDICINE; HODGKIN DISEASE; HUMAN; IMAGE RETRIEVAL; INFORMATION PROCESSING; INFORMATION STORAGE; INFORMED CONSENT; INTERNET; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT INFORMATION; PICTURE ARCHIVING AND COMMUNICATION SYSTEM; POSITRON EMISSION TOMOGRAPHY; TELERADIOLOGY;

ADOLESCENT; CHILD; CLINICAL TRIALS AS TOPIC; COMPUTER COMMUNICATION NETWORKS; COMPUTER SECURITY; DATA COLLECTION; DATABASE MANAGEMENT SYSTEMS; DIAGNOSTIC IMAGING; EUROPE; EUROPEAN UNION; HODGKIN DISEASE; HUMANS; MULTICENTER STUDIES AS TOPIC; QUALITY CONTROL; RADIOLOGY INFORMATION SYSTEMS;

EID: 84887841775     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0033-1354416     Document Type: Article

References (27)

1. Bhatia S., Yasui Y., Robison L. L. et al. Late effects study group: High risk of subsequent neoplasm continues with extended follow-up of childhood Hodgkin's lymphoma: Report from the late effects study group. JCO: 2003; 21 4386 4394 (Pubitemid 46621816)
2. Creutzig U., Jürgens H., Herold R. et al. Konzepte der GPOH und des Kompetenznetzes zur Weiterentwicklung und Qualitätssicherung in der Pädiatrischen Onkologie. Klin Pädiatr: 2004; 216 379 383 (Pubitemid 39524573)
3. Dieckmann K., Pötter R., Wagner W. et al. Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin's disease trial with 71 participating hospitals: The experience of the German-Austrian pediatric multicenter trial DAL-HD-90. Radiother Oncol: 2002; 62 191 200 (Pubitemid 34286452)
4. Dieckmann K., Pötter R., Hofmann J. et al. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian pediatric multicenter trial DAL-HD-90. Int J Rad Oncol Biol Phys: 2003; 56 644 652 (Pubitemid 36677356)
5. Dörffel W., Albrecht M., Lüders H. et al. Multinationale Therapiestudie für den Morbus Hodgkin bei Kindern und Jugendlichen GPOH-HD95. Zwischenbericht nach 2 1/2 Jahren. Klin Padiatr: 1998; 210 212 219 (Pubitemid 28361242)
6. Dörffel W., Lüders H., Rühl U. et al. Preliminary results of multicenter trial GPOH-HD95 for treatment of Hodgkin's disease in children and adolescents: Analysis and Outlook. Klin Padiatr: 2003; 215 139 145 (Pubitemid 36718285)
7. Dörffel W., Rühl U., Lüders H. et al. Treatment of children and adolescents with Hodgkin Lymphoma without radiotherapy for patients in compete remission after chemotherapy: Final results of the multinational trial GPOH-HD95. JCO: 2013; 31 1562 1568
8. Haase R., Vilser C., Mauz-Körholz C. et al. Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical Hodgkin's lymphoma (HL). Klin Pädiatr: 2012; 224 377 381
9. Hall G. W., Katzilakis N., Pinkerton C. R. et al. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - A Children's Cancer and Leukaemia Group report. British Journal of Haematology: 2007; 138 761 768 (Pubitemid 47313220)
10. http://ec.europa.eu/justice/data-protection/law/status-implementation/ index-en.htm#h2-5
11. http://europa.eu/legislation-summaries/information-society/ data-protection/14012-en.htm
12. Kluge R., Körholz D. Die Bedeutung der FDG-PET für die Stadieneinteilung und Therapie des Hodgkin-Lymphoms im Kindesalter. Klin Padiatr: 2012; 223 315 319
13. Körholz D., Claviez A., Hasenclever D. et al. The concept of the GPOH-HD-2003 therapy study for pediatric Hodgkin's disease: Evolution in the tradition of the DAL/GPOH studies. Klin Padiatr: 2004; 216 150 156 (Pubitemid 38797641)
14. Körholz D., Kluge R., Wickmann L. et al. Importance of F18-Fluorodeoxy-D-2-Glucose Positron Emission Tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence - Consequences for the GPOH-HD 2003 protocol. Onkologie: 2003; 26 489 493 (Pubitemid 37409896)
15. Körholz D. Data security concept for the Clinical Reference Centre of the GPOH-HD study group taking particular account of the tele-radiology platform in the European Paediatric Hodgkin's Network (EuroNet-PHL-TRP) for the exchange of treatment data and medical imaging data in the context of the EuroNet-PHL study group's network.
16. Kurch L., Hasenclever D., Elsner A. et al. Semiautomatic approach for discrimination between adequate and inadequate early response in FDG-PET/CT of paediatric Hodgkin lymphoma patients. Journal of Nuclear Medicine: 2012; 53 Supplement 1 155
17. Lüders H. Vergleich der Behandlungsergebnisse der Studien GPOH-HD 95 und HD-Intervall zur Behandlung des Hodgkin Lymphoms im Kindes- und Jugendalter: Bedeutung der zentralen Referenzbegutachtung für die optimale Diagnostik und den Behandlungserfolg. Dissertation an der Martin-Luther- Universität Halle/Saale: 2011
18. Mauz-Körholz C., Hasenclever D., Dörffel W. et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 Study. JCO: 2010; 28 3680 3686
19. Mauz-Körholz C., Gorde-Grosjean S., Hasenclever D. et al. Resection alone in 58 children with limited stage Lymphocyte-predominant Hodgkin lymphoma - Experience from the European Network Group on Pediatric Hodgkin lymphoma. Cancer: 2007; 110 179 185 (Pubitemid 46986431)
20. Niehues T., Schellong G., Dörffel W. et al. Immunodeficiency and Hodgkin's disease: Treatment and outcome in the DAL HD 78-90 and GPOH-HD95 studies. Klin Padiatr: 2003; 215 315 320 (Pubitemid 38064629)
21. 18F] Fluorodeoxyglucose Positron Emission Tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. JCO: 2011; 29 3523 3528
22. Schellong G. The balance between cure and late effects in childhood Hodgkin's lymphoma: The experience of the German-Austrian Study Group since 1978. German-Austrian Pediatric Hodgkin' Disease Study Group. Annals of Oncology: 1996; 7 Supp 4 67 72
23. Schellong G., Pötter R., Brämsweg J. et al. High cure rates and reduced long term toxicity in pediatric Hodgkin's disease: The German-Austrian Multicenter Trial DAL-HD-90. JCO: 1999; 17 3736 3744
24. Schellong G., Riephausen M., Bruch C. et al. Late Valvular and other Cardiac Diseases after different doses of mediastinal radiotherapy for Hodgkin disease in childhood and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD Studies. Ped Blood Cancer: 2010; 55 1145 1152
25. Spitzer M., Ullrich T., Ueckert F. Securing a web-based teleradiology platform according to German la wand best practices. Stud Health Technol Inform: 2009; 150 730 734
26. Ueckert F. K., Prokoschl H. U. Implementing Security and Access Control Mechanisms for an electronic healthcare record. Proc AMIA Symp: 2002; 825 829
27. Wickmann L., Lüders H., Dörffel W. 18-FDG-PET-Befunde bei Kindern und Jugendlichen mit Morbus Hodgkin: Retrospektive Auswertung zur Korrelation mit anderen bildgebenden Verfahren bei der initialen Stagingdiagnostik und zum prädiktiven Wert bei Verlaufsuntersuchungen. Klin Padiatr: 2003; 215 146 150 (Pubitemid 36718286)